Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

We are certainly in buying territory now.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Stockfun1 Member Profile
 
Followed By 16
Posts 805
Boards Moderated 0
Alias Born 07/23/17
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/8/2021 1:05:46 PM
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire Inc. - 1/4/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 7:02:09 AM
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 12/17/2020 6:30:00 AM
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire - 12/9/2020 3:49:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 12:31:08 PM
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire Inc. - 12/4/2020 11:30:00 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy S... GlobeNewswire Inc. - 11/23/2020 11:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2020 7:17:39 AM
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/9/2020 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:16:27 PM
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the... GlobeNewswire Inc. - 10/15/2020 3:06:10 PM
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder... GlobeNewswire Inc. - 10/15/2020 3:05:10 PM
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACA... GlobeNewswire Inc. - 10/8/2020 8:32:10 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16... GlobeNewswire Inc. - 10/8/2020 8:30:10 AM
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire Inc. - 9/17/2020 1:55:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 7:02:02 AM
Zynerba Pharmaceuticals Provides Update on Recent Milestones GlobeNewswire Inc. - 9/14/2020 6:55:10 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 9/10/2020 7:30:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 9:28:55 AM
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 8/10/2020 6:45:10 AM
Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Con... GlobeNewswire Inc. - 7/22/2020 6:50:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 10:43:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/30/2020 6:59:54 AM
Stockfun1   Saturday, 09/12/20 09:59:43 PM
Re: dhbuzz post# 2579
Post # of 2639 
We are certainly in buying territory now. I may be averaging down this week. Trying to beat any announcements. I don’t think Zynerba can have any further appreciable drop below $3.50.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences




Ticker News is disabled